|
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
|
94-2573850
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.001 Par Value
|
QDEL
|
NASDAQ Global Market
|
Large accelerated filer
|
x
|
|
Accelerated filer
|
¨
|
Non-accelerated filer
|
¨
|
|
Smaller reporting company
|
¨
|
|
|
|
Emerging growth company
|
¨
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
¨
|
|
|
|
|
|
|
|
|
March 31,
2019 |
|
December 31,
2018 |
||||
ASSETS
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
56,938
|
|
|
$
|
43,695
|
|
Accounts receivable, net
|
69,234
|
|
|
58,677
|
|
||
Inventories
|
66,647
|
|
|
67,379
|
|
||
Prepaid expenses and other current assets
|
18,823
|
|
|
23,646
|
|
||
Total current assets
|
211,642
|
|
|
193,397
|
|
||
Property, plant and equipment, net
|
75,356
|
|
|
73,901
|
|
||
Right-of-use assets
|
85,907
|
|
|
—
|
|
||
Goodwill
|
337,019
|
|
|
337,021
|
|
||
Intangible assets, net
|
168,120
|
|
|
175,029
|
|
||
Deferred tax asset—non-current
|
22,102
|
|
|
22,192
|
|
||
Other non-current assets
|
5,709
|
|
|
4,831
|
|
||
Total assets
|
$
|
905,855
|
|
|
$
|
806,371
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
||||
Current liabilities:
|
|
|
|
||||
Accounts payable
|
$
|
26,827
|
|
|
$
|
25,171
|
|
Accrued payroll and related expenses
|
10,969
|
|
|
19,210
|
|
||
Current portion of operating lease liabilities
|
5,385
|
|
|
—
|
|
||
Current portion of contingent consideration
|
3,971
|
|
|
3,983
|
|
||
Current portion of deferred consideration
|
44,000
|
|
|
44,000
|
|
||
Current portion of Convertible Senior Notes
|
54,880
|
|
|
54,379
|
|
||
Other current liabilities
|
13,521
|
|
|
12,992
|
|
||
Total current liabilities
|
159,553
|
|
|
159,735
|
|
||
Operating lease liabilities
|
83,818
|
|
|
—
|
|
||
Revolving Credit Facility
|
33,188
|
|
|
53,188
|
|
||
Deferred consideration
|
145,501
|
|
|
143,158
|
|
||
Contingent consideration
|
15,129
|
|
|
15,129
|
|
||
Other non-current liabilities
|
7,968
|
|
|
9,577
|
|
||
Commitments and contingencies (see Note 8)
|
|
|
|
||||
Stockholders’ equity:
|
|
|
|
||||
Preferred stock, $.001 par value per share; 5,000 shares authorized; none issued or outstanding at March 31, 2019 and December 31, 2018
|
—
|
|
|
—
|
|
||
Common stock, $.001 par value per share; 97,500 shares authorized; 39,806 and 39,386 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively
|
40
|
|
|
39
|
|
||
Additional paid-in capital
|
374,148
|
|
|
363,921
|
|
||
Accumulated other comprehensive loss
|
(97
|
)
|
|
(139
|
)
|
||
Retained earnings
|
86,607
|
|
|
61,763
|
|
||
Total stockholders’ equity
|
460,698
|
|
|
425,584
|
|
||
Total liabilities and stockholders’ equity
|
$
|
905,855
|
|
|
$
|
806,371
|
|
|
Three months ended
March 31, |
||||||
|
2019
|
|
2018
|
||||
Total revenues
|
$
|
147,968
|
|
|
$
|
169,143
|
|
Cost of sales
|
57,041
|
|
|
62,872
|
|
||
Gross profit
|
90,927
|
|
|
106,271
|
|
||
Research and development
|
13,930
|
|
|
12,621
|
|
||
Sales and marketing
|
29,589
|
|
|
28,558
|
|
||
General and administrative
|
13,431
|
|
|
10,532
|
|
||
Acquisition and integration costs
|
2,824
|
|
|
3,467
|
|
||
Total operating expenses
|
59,774
|
|
|
55,178
|
|
||
Operating income
|
31,153
|
|
|
51,093
|
|
||
Other expense, net:
|
|
|
|
||||
Interest expense, net
|
(4,582
|
)
|
|
(7,850
|
)
|
||
Loss on extinguishment of debt
|
—
|
|
|
(4,567
|
)
|
||
Total other expense, net
|
(4,582
|
)
|
|
(12,417
|
)
|
||
Income before income taxes
|
26,571
|
|
|
38,676
|
|
||
Provision for income taxes
|
1,727
|
|
|
4,718
|
|
||
Net income
|
$
|
24,844
|
|
|
$
|
33,958
|
|
Basic earnings per share
|
$
|
0.63
|
|
|
$
|
0.96
|
|
Diluted earnings per share
|
$
|
0.60
|
|
|
$
|
0.86
|
|
Shares used in basic per share calculation
|
39,704
|
|
|
35,236
|
|
||
Shares used in diluted per share calculation
|
42,907
|
|
|
41,948
|
|
|
Three months ended
March 31, |
||||||
|
2019
|
|
2018
|
||||
Net income
|
$
|
24,844
|
|
|
$
|
33,958
|
|
Changes in cumulative translation adjustment, net of tax
|
(248
|
)
|
|
20
|
|
||
Change in fair value of cash flow hedges, net of tax
|
290
|
|
|
—
|
|
||
Comprehensive income
|
$
|
24,886
|
|
|
$
|
33,978
|
|
|
Common Stock
|
|
|
|
|
|
|
|||||||||||||||
|
Shares
|
|
Par
|
|
Additional
paid-in
capital
|
|
Accumulated
other
comprehensive
(loss) income
|
|
Retained
earnings
|
|
Total
stockholders’
equity
|
|||||||||||
Balance at December 31, 2018
|
39,386
|
|
|
$
|
39
|
|
|
$
|
363,921
|
|
|
$
|
(139
|
)
|
|
$
|
61,763
|
|
|
$
|
425,584
|
|
Issuance of common stock under equity compensation plans
|
444
|
|
|
1
|
|
|
8,816
|
|
|
—
|
|
|
—
|
|
|
8,817
|
|
|||||
Stock-based compensation expense
|
—
|
|
|
—
|
|
|
2,887
|
|
|
—
|
|
|
—
|
|
|
2,887
|
|
|||||
Repurchases of common stock
|
(24
|
)
|
|
—
|
|
|
(1,476
|
)
|
|
—
|
|
|
—
|
|
|
(1,476
|
)
|
|||||
Changes in cumulative translation adjustment, net of tax
|
—
|
|
|
—
|
|
|
—
|
|
|
(248
|
)
|
|
—
|
|
|
(248
|
)
|
|||||
Change in fair value of cash flow hedges, net of tax
|
—
|
|
|
—
|
|
|
—
|
|
|
290
|
|
|
—
|
|
|
290
|
|
|||||
Net income
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
24,844
|
|
|
24,844
|
|
|||||
Balance at March 31, 2019
|
39,806
|
|
|
$
|
40
|
|
|
$
|
374,148
|
|
|
$
|
(97
|
)
|
|
$
|
86,607
|
|
|
$
|
460,698
|
|
|
Common Stock
|
|
|
|
|
|
|
|||||||||||||||
|
Shares
|
|
Par
|
|
Additional
paid-in
capital
|
|
Accumulated
other
comprehensive income
|
|
Retained
earnings (accumulated
deficit)
|
|
Total
stockholders’
equity
|
|||||||||||
Balance at December 31, 2017
|
34,540
|
|
|
$
|
35
|
|
|
$
|
239,489
|
|
|
$
|
—
|
|
|
$
|
(12,420
|
)
|
|
$
|
227,104
|
|
Issuance of common stock under equity compensation plans
|
516
|
|
|
—
|
|
|
5,652
|
|
|
—
|
|
|
—
|
|
|
5,652
|
|
|||||
Stock-based compensation expense
|
—
|
|
|
—
|
|
|
2,936
|
|
|
—
|
|
|
—
|
|
|
2,936
|
|
|||||
Issuance of shares in exchange for Convertible Senior Notes
|
2,428
|
|
|
2
|
|
|
118,073
|
|
|
—
|
|
|
—
|
|
|
118,075
|
|
|||||
Reduction for equity component of Convertible Senior Notes exchanged
|
—
|
|
|
—
|
|
|
(53,867
|
)
|
|
—
|
|
|
—
|
|
|
(53,867
|
)
|
|||||
Repurchases of common stock
|
(73
|
)
|
|
—
|
|
|
(3,232
|
)
|
|
—
|
|
|
—
|
|
|
(3,232
|
)
|
|||||
Changes in cumulative translation adjustment, net of tax
|
—
|
|
|
—
|
|
|
—
|
|
|
20
|
|
|
—
|
|
|
20
|
|
|||||
Net income
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
33,958
|
|
|
33,958
|
|
|||||
Balance at March 31, 2018
|
37,411
|
|
|
$
|
37
|
|
|
$
|
309,051
|
|
|
$
|
20
|
|
|
$
|
21,538
|
|
|
$
|
330,646
|
|
QUIDEL CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands; unaudited)
|
|||||||
|
Three months ended
March 31, |
||||||
|
2019
|
|
2018
|
||||
OPERATING ACTIVITIES:
|
|
|
|
||||
Net income
|
$
|
24,844
|
|
|
$
|
33,958
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
||||
Depreciation, amortization and other
|
11,971
|
|
|
12,075
|
|
||
Stock-based compensation expense
|
3,588
|
|
|
2,936
|
|
||
Amortization of debt discount and deferred issuance costs
|
602
|
|
|
1,671
|
|
||
Accretion of interest on deferred consideration
|
2,343
|
|
|
2,793
|
|
||
Amortization of inventory step-up to fair value
|
—
|
|
|
3,650
|
|
||
Loss on extinguishment of debt
|
—
|
|
|
4,567
|
|
||
Changes in assets and liabilities:
|
|
|
|
||||
Accounts receivable
|
(10,682
|
)
|
|
(25,205
|
)
|
||
Inventories
|
682
|
|
|
5,471
|
|
||
Prepaid expenses and other current and non-current assets
|
3,995
|
|
|
(1,842
|
)
|
||
Accounts payable
|
1,802
|
|
|
(595
|
)
|
||
Accrued payroll and related expenses
|
(6,969
|
)
|
|
(5,988
|
)
|
||
Other current and non-current liabilities
|
721
|
|
|
2,323
|
|
||
Net cash provided by operating activities:
|
32,897
|
|
|
35,814
|
|
||
INVESTING ACTIVITIES:
|
|
|
|
||||
Acquisitions of property and equipment
|
(4,993
|
)
|
|
(4,949
|
)
|
||
Proceeds from sale of Summers Ridge Property
|
—
|
|
|
146,644
|
|
||
Net cash (used for) provided by investing activities:
|
(4,993
|
)
|
|
141,695
|
|
||
FINANCING ACTIVITIES:
|
|
|
|
||||
Proceeds from issuance of common stock
|
6,847
|
|
|
5,652
|
|
||
Payments on Revolving Credit Facility
|
(20,000
|
)
|
|
(10,000
|
)
|
||
Payments on finance lease obligation
|
(38
|
)
|
|
(29
|
)
|
||
Repurchases of common stock
|
(1,476
|
)
|
|
(3,232
|
)
|
||
Payments of acquisition contingent consideration
|
(12
|
)
|
|
(1,017
|
)
|
||
Payments of Term Loan
|
—
|
|
|
(101,813
|
)
|
||
Transaction costs related to debt exchange
|
—
|
|
|
(1,357
|
)
|
||
Net cash used for financing activities:
|
(14,679
|
)
|
|
(111,796
|
)
|
||
Effect of exchange rates on cash
|
18
|
|
|
13
|
|
||
Net increase in cash and cash equivalents
|
13,243
|
|
|
65,726
|
|
||
Cash and cash equivalents, beginning of period
|
43,695
|
|
|
36,086
|
|
||
Cash and cash equivalents, end of period
|
$
|
56,938
|
|
|
$
|
101,812
|
|
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING TRANSACTIONS:
|
|||||||
Purchase of property and equipment by incurring current liabilities
|
$
|
1,728
|
|
|
$
|
2,067
|
|
NON-CASH FINANCING ACTIVITIES:
|
|
|
|
||||
Reduction of other current liabilities upon issuance of restricted share units
|
$
|
1,970
|
|
|
$
|
—
|
|
Extinguishment of Convertible Senior Notes through issuance of common stock
|
$
|
—
|
|
|
$
|
118,075
|
|
Consolidated Balance Sheet (in thousands)
|
January 1,
2019 |
|
Effect of Change in Accounting Principle
|
|
After change in Accounting Principle
|
||||||
ASSETS
|
|
|
|
|
|
||||||
Operating lease right-of-use asset
|
$
|
—
|
|
|
$
|
87,086
|
|
|
$
|
87,086
|
|
Total assets
|
$
|
806,371
|
|
|
$
|
87,086
|
|
|
$
|
893,457
|
|
|
|
|
|
|
|
||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
||||||
Current portion of operating lease liability
|
$
|
—
|
|
|
$
|
5,290
|
|
|
$
|
5,290
|
|
Other current liabilities
|
12,992
|
|
|
(448
|
)
|
|
12,544
|
|
|||
Total current liabilities
|
159,735
|
|
|
4,842
|
|
|
164,577
|
|
|||
Operating lease liability
|
—
|
|
|
84,866
|
|
|
84,866
|
|
|||
Other non-current liabilities
|
9,577
|
|
|
(2,622
|
)
|
|
6,955
|
|
|||
Total liabilities and stockholders’ equity
|
$
|
806,371
|
|
|
$
|
87,086
|
|
|
$
|
893,457
|
|
|
Three months ended
March 31, |
||||||
|
2019
|
|
2018
|
||||
Numerator:
|
|
|
|
||||
Net income used for basic earnings per share
|
$
|
24,844
|
|
|
$
|
33,958
|
|
Interest expense on Convertible Senior Notes, net of tax
|
791
|
|
|
2,144
|
|
||
Net income used for diluted earnings per share, if-converted method
|
$
|
25,635
|
|
|
$
|
36,102
|
|
|
|
|
|
||||
Basic weighted-average common shares outstanding
|
39,704
|
|
|
35,236
|
|
||
Potentially dilutive shares issuable from Convertible Senior Notes, if-converted
|
1,825
|
|
|
4,957
|
|
||
Potentially dilutive shares issuable from stock options and unvested RSUs
|
1,378
|
|
|
1,755
|
|
||
Diluted weighted-average common shares outstanding, if-converted
|
42,907
|
|
|
41,948
|
|
||
Potentially dilutive shares excluded from calculation due to anti-dilutive effect
|
149
|
|
|
193
|
|
|
March 31,
2019 |
|
December 31,
2018 |
||||
Raw materials
|
$
|
24,783
|
|
|
$
|
24,292
|
|
Work-in-process (materials, labor and overhead)
|
20,860
|
|
|
21,280
|
|
||
Finished goods (materials, labor and overhead)
|
21,004
|
|
|
21,807
|
|
||
Total inventories
|
$
|
66,647
|
|
|
$
|
67,379
|
|
|
March 31,
2019 |
|
December 31,
2018 |
||||
Receivables under transition service agreements
|
$
|
9,192
|
|
|
$
|
15,507
|
|
Income taxes receivable
|
2,703
|
|
|
2,703
|
|
||
Prepaid expenses
|
5,375
|
|
|
4,508
|
|
||
Other
|
1,553
|
|
|
928
|
|
||
Total prepaid expenses and other current assets
|
$
|
18,823
|
|
|
$
|
23,646
|
|
|
March 31,
2019 |
|
December 31,
2018 |
||||
Customer incentives
|
$
|
5,778
|
|
|
$
|
7,516
|
|
Accrued interest
|
690
|
|
|
347
|
|
||
Other
|
7,053
|
|
|
5,129
|
|
||
Total other current liabilities
|
$
|
13,521
|
|
|
$
|
12,992
|
|
|
March 31,
2019 |
|
December 31,
2018 |
||||
Principal amount outstanding
|
$
|
58,503
|
|
|
$
|
58,503
|
|
Unamortized discount of liability component
|
(3,195
|
)
|
|
(3,637
|
)
|
||
Unamortized debt issuance costs
|
(428
|
)
|
|
(487
|
)
|
||
Net carrying amount of liability component
|
54,880
|
|
|
54,379
|
|
||
Less: current portion
|
(54,880
|
)
|
|
(54,379
|
)
|
||
Long-term debt
|
$
|
—
|
|
|
$
|
—
|
|
Carrying value of equity component, net of issuance costs
|
$
|
10,092
|
|
|
$
|
10,092
|
|
Fair value of outstanding Convertible Senior Notes
|
$
|
119,767
|
|
|
$
|
85,999
|
|
Remaining amortization period of discount on the liability component
|
1.8 years
|
|
|
2.0 years
|
|
|
Number
of Shares
|
|
Weighted-
average exercise
price per
share
|
|||
Outstanding at December 31, 2018
|
1,877
|
|
|
$
|
21.53
|
|
Granted
|
168
|
|
|
59.18
|
|
|
Exercised
|
(355
|
)
|
|
17.77
|
|
|
Cancelled
|
(2
|
)
|
|
37.37
|
|
|
Outstanding at March 31, 2019
|
1,688
|
|
|
$
|
26.06
|
|
|
Shares
|
|
Weighted-average
grant date
fair value
|
|||
Non-vested at December 31, 2018
|
676
|
|
|
$
|
30.75
|
|
Granted
|
220
|
|
|
59.45
|
|
|
Vested
|
(68
|
)
|
|
21.45
|
|
|
Forfeited
|
(2
|
)
|
|
42.51
|
|
|
Non-vested at March 31, 2019
|
826
|
|
|
$
|
39.11
|
|
|
Three months ended
March 31, |
|||||||
|
2019
|
|
2018
|
|||||
Cost of sales
|
$
|
280
|
|
|
$
|
231
|
|
|
Research and development
|
565
|
|
|
592
|
|
|||
Sales and marketing
|
1,119
|
|
|
796
|
|
|||
General and administrative
|
1,624
|
|
|
1,317
|
|
|||
Total stock-based compensation expense
|
$
|
3,588
|
|
|
$
|
2,936
|
|
|
Three months ended
March 31, |
||||||
|
2019
|
|
2018
|
||||
Risk-free interest rate
|
2.51
|
%
|
|
2.49
|
%
|
||
Expected option life (in years)
|
5.68
|
|
|
6.29
|
|
||
Volatility rate
|
39
|
%
|
|
36
|
%
|
||
Dividend rate
|
—
|
%
|
|
—
|
%
|
||
Weighted-average grant date fair value
|
$
|
23.67
|
|
|
$
|
18.76
|
|
|
Three months ended
March 31, |
||||||
|
2019
|
|
2018
|
||||
Rapid Immunoassay
|
$
|
62,494
|
|
|
$
|
80,685
|
|
Cardiac Immunoassay
|
65,872
|
|
|
68,444
|
|
||
Specialized Diagnostic Solutions
|
13,854
|
|
|
14,871
|
|
||
Molecular Diagnostic Solutions
|
5,748
|
|
|
5,143
|
|
||
Total revenues
|
$
|
147,968
|
|
|
$
|
169,143
|
|
|
Three months ended
|
||
|
March 31,
2019 |
||
Finance lease ROU asset amortization
|
$
|
63
|
|
Finance lease interest expense
|
209
|
|
|
Total finance lease costs
|
272
|
|
|
Operating lease costs
|
2,505
|
|
|
Total lease costs
|
$
|
2,777
|
|
|
|
||
Cash paid for amounts included in the measurement of operating lease liabilities
|
|
||
Operating cash flows from operating leases
|
$
|
2,280
|
|
Operating cash flows from finance leases
|
$
|
209
|
|
Right-of-use assets obtained in exchange for new lease liabilities
|
|
||
Operating leases
|
$
|
328
|
|
Finance leases
|
$
|
1,326
|
|
Years ending December 31,
|
|
Operating
|
|
Finance
|
||||
2019
|
|
$
|
6,918
|
|
|
$
|
989
|
|
2020
|
|
9,340
|
|
|
1,262
|
|
||
2021
|
|
9,576
|
|
|
1,270
|
|
||
2022
|
|
8,568
|
|
|
1,281
|
|
||
2023
|
|
8,184
|
|
|
1,291
|
|
||
Thereafter
|
|
76,566
|
|
|
3,129
|
|
||
Total lease payments
|
|
119,152
|
|
|
9,222
|
|
||
Less: imputed interest
|
|
(29,949
|
)
|
|
(4,076
|
)
|
||
Total
|
|
$
|
89,203
|
|
|
$
|
5,146
|
|
Less: current portion of operating lease liability
|
|
(5,385
|
)
|
|
(478
|
)
|
||
Non-current portion of operating lease liability
|
|
$
|
83,818
|
|
|
$
|
4,668
|
|
|
|
|
|
|
||||
Weighted average remaining lease term (in years)
|
|
12.7
|
|
|
6.3
|
|
||
Weighted average discount rate
|
|
4
|
%
|
|
18
|
%
|
|
March 31, 2019
|
|
December 31, 2018
|
||||||||||||||||||||||||||||
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||||||||||
Assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Derivative assets
|
$
|
—
|
|
|
$
|
361
|
|
|
$
|
—
|
|
|
$
|
361
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Total assets measured at fair value
|
$
|
—
|
|
|
$
|
361
|
|
|
$
|
—
|
|
|
$
|
361
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
—
|
|
Liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||
Contingent consideration
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
19,100
|
|
|
$
|
19,100
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
19,112
|
|
|
$
|
19,112
|
|
Deferred consideration
|
—
|
|
|
189,501
|
|
|
—
|
|
|
189,501
|
|
|
—
|
|
|
187,158
|
|
|
—
|
|
|
187,158
|
|
||||||||
Total liabilities measured at fair value
|
$
|
—
|
|
|
$
|
189,501
|
|
|
$
|
19,100
|
|
|
$
|
208,601
|
|
|
$
|
—
|
|
|
$
|
187,158
|
|
|
$
|
19,112
|
|
|
$
|
206,270
|
|
|
Contingent consideration liabilities
(Level 3 measurement) |
||
Balance at December 31, 2018
|
$
|
19,112
|
|
Cash payments
|
(12
|
)
|
|
Balance at March 31, 2019
|
$
|
19,100
|
|
|
March 31, 2019
|
||||||
|
Notional Amount
|
|
Fair Value, Net
|
||||
Prepaid expenses and other current assets
|
$
|
14,121
|
|
|
$
|
361
|
|
|
Three months ended
March 31, |
|
Increase (Decrease)
|
|||||||||||
|
2019
|
|
2018
|
|
$
|
|
%
|
|||||||
Rapid Immunoassay
|
$
|
62,494
|
|
|
$
|
80,685
|
|
|
$
|
(18,191
|
)
|
|
(23
|
)%
|
Cardiac Immunoassay
|
65,872
|
|
|
68,444
|
|
|
(2,572
|
)
|
|
(4
|
)%
|
|||
Specialized Diagnostic Solutions
|
13,854
|
|
|
14,871
|
|
|
(1,017
|
)
|
|
(7
|
)%
|
|||
Molecular Diagnostic Solutions
|
5,748
|
|
|
5,143
|
|
|
605
|
|
|
12
|
%
|
|||
Total revenues
|
$
|
147,968
|
|
|
$
|
169,143
|
|
|
$
|
(21,175
|
)
|
|
(13
|
)%
|
|
Three months ended
March 31, |
|
|
|
|
|||||||||||||||
|
2019
|
|
2018
|
|
|
|
|
|||||||||||||
|
Operating
expenses |
|
As a % of
total revenues |
|
Operating
expenses |
|
As a % of
total revenues |
|
Increase (Decrease)
|
|||||||||||
|
$
|
|
%
|
|||||||||||||||||
Research and development
|
$
|
13,930
|
|
|
9
|
%
|
|
$
|
12,621
|
|
|
7
|
%
|
|
$
|
1,309
|
|
|
10
|
%
|
Sales and marketing
|
$
|
29,589
|
|
|
20
|
%
|
|
$
|
28,558
|
|
|
17
|
%
|
|
$
|
1,031
|
|
|
4
|
%
|
General and administrative
|
$
|
13,431
|
|
|
9
|
%
|
|
$
|
10,532
|
|
|
6
|
%
|
|
$
|
2,899
|
|
|
28
|
%
|
Acquisition and integration costs
|
$
|
2,824
|
|
|
2
|
%
|
|
$
|
3,467
|
|
|
2
|
%
|
|
$
|
(643
|
)
|
|
(19
|
)%
|
|
March 31, 2019
|
|
December 31, 2018
|
||||
Cash and cash equivalents
|
$
|
56,938
|
|
|
$
|
43,695
|
|
Amount available to borrow under the Revolving Credit Facility
|
$
|
141,812
|
|
|
$
|
121,812
|
|
Working capital including cash and cash equivalents
|
$
|
52,089
|
|
|
$
|
33,662
|
|
Adjusted working capital (1)
|
$
|
106,969
|
|
|
$
|
88,041
|
|
•
|
support of commercialization efforts related to our current and future products, including support of our direct sales force and field support resources both in the United States and abroad;
|
•
|
interest on and repayments of our Convertible Senior Notes, Revolving Credit Facility, deferred consideration, contingent consideration and lease obligations;
|
•
|
the continued advancement of research and development efforts;
|
•
|
acquisitions of equipment and other fixed assets for use in our current and future manufacturing and research and development facilities;
|
•
|
the integration of our recent acquisitions; and
|
•
|
potential strategic acquisitions and investments.
|
•
|
our ability to successfully integrate our recently acquired businesses;
|
•
|
our ability to realize revenue growth from our new technologies and create innovative products in our markets;
|
•
|
our outstanding debt and covenant restrictions;
|
•
|
our ability to leverage our operating expenses to realize operating profits as we grow revenue;
|
•
|
competing technological and market developments; and
|
•
|
the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings.
|
|
Three months ended
March 31, |
||||||
|
2019
|
|
2018
|
||||
Net cash provided by operating activities:
|
$
|
32,897
|
|
|
$
|
35,814
|
|
Net cash (used for) provided by investing activities:
|
(4,993
|
)
|
|
141,695
|
|
||
Net cash used for financing activities:
|
(14,679
|
)
|
|
(111,796
|
)
|
||
Effect of exchange rates on cash
|
18
|
|
|
13
|
|
||
Net increase in cash and cash equivalents
|
$
|
13,243
|
|
|
$
|
65,726
|
|
|
Three months ended
March 31, |
||
Currency
|
2019
|
||
Chinese Yuan
|
$
|
146
|
|
Euro
|
$
|
111
|
|
Period
|
|
Total number
of shares
purchased (1)
|
|
Average
price paid
per share
|
|
Total number
of shares purchased
as part of publicly
announced plans or programs
|
|
Approximate dollar
value of shares that
may yet be
purchased
under the plans
or programs (2)
|
||||||
December 31, 2018 - January 27, 2019
|
|
1,573
|
|
|
$
|
52.99
|
|
|
—
|
|
|
$
|
50,000,000
|
|
January 28, 2019 - February 24, 2019
|
|
20,262
|
|
|
60.01
|
|
|
—
|
|
|
50,000,000
|
|
||
February 25, 2019 - March 31, 2019
|
|
2,625
|
|
|
67.16
|
|
|
—
|
|
|
50,000,000
|
|
||
Total
|
|
24,460
|
|
|
$
|
60.33
|
|
|
—
|
|
|
$
|
50,000,000
|
|
|
|
|
3.1
|
|
|
3.2
|
|
|
3.3
|
|
|
4.1
|
|
|
10.1(1)*
|
|
|
31.1*
|
|
|
31.2*
|
|
|
32.1**
|
|
|
101.INS*
|
|
XBRL Instance Document
|
101.SCH*
|
|
XBRL Taxonomy Extension Schema Document
|
101.CAL*
|
|
XBRL Taxonomy Calculation Linkbase Document
|
101.DEF*
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
101.LAB*
|
|
XBRL Taxonomy Label Linkbase Document
|
101.PRE*
|
|
XBRL Taxonomy Presentation Linkbase Document
|
|
|
Date: May 8, 2019
|
QUIDEL CORPORATION
|
|
|
|
/s/ DOUGLAS C. BRYANT
|
|
Douglas C. Bryant
|
|
President and Chief Executive Officer
(Principal Executive Officer)
|
|
|
|
/s/ RANDALL J. STEWARD
|
|
Randall J. Steward
|
|
Chief Financial Officer
(Principal Financial Officer)
|
Exhibit
Number |
|
|
3.1
|
|
|
3.2
|
|
|
3.3
|
|
|
4.1
|
|
|
10.1(1)*
|
|
|
31.1*
|
|
|
31.2*
|
|
|
32.1**
|
|
|
101.INS*
|
|
XBRL Instance Document
|
101.SCH*
|
|
XBRL Taxonomy Extension Schema Document
|
101.CAL*
|
|
XBRL Taxonomy Calculation Linkbase Document
|
101.DEF*
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
101.LAB*
|
|
XBRL Taxonomy Label Linkbase Document
|
101.PRE*
|
|
XBRL Taxonomy Presentation Linkbase Document
|
Quidel Corporation
|
|
Karen Gibson
|
12544 High Bluff Drive, Suite 200
|
|
|
San Diego, CA 92130
|
|
|
Attn: President & CEO
|
|
|
|
QUIDEL CORPORATION, a Delaware corporation
|
|
|
|
|
|
By:
|
/s/ DOUGLAS C. BRYANT
|
|
|
Printed Name: Douglas C. Bryant
|
|
|
Title: President & CEO
|
|
|
Quidel Corporation
|
|
|
|
|
|
|
|
|
EXECUTIVE
|
|
|
|
|
|
|
|
By:
|
/s/ KAREN GIBSON
|
|
|
Karen Gibson
|
1.
|
I have reviewed this quarterly report on Form 10-Q of Quidel Corporation;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
|
/s/ DOUGLAS C. BRYANT
|
|
Douglas C. Bryant
|
|
President and Chief Executive Officer
|
|
(Principal Executive Officer)
|
1.
|
I have reviewed this quarterly report on Form 10-Q of Quidel Corporation;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
|
/s/ RANDALL J. STEWARD
|
|
Randall J. Steward
|
|
Chief Financial Officer
|
|
(Principal Financial Officer)
|
•
|
the Company’s Quarterly Report on Form 10-Q for the period ended
March 31, 2019
(the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
•
|
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
/s/ DOUGLAS C. BRYANT
|
Douglas C. Bryant
|
President and Chief Executive Officer
|
(Principal Executive Officer)
|
|
/s/ RANDALL J. STEWARD
|
Randall J. Steward
|
Chief Financial Officer
|
(Principal Financial Officer)
|